Concord Biotech Q4 Profits Decline 37% Amid Margin Compression
Financial Performance Overview Concord Biotech, a prominent player in the global biopharmaceutical sector, reported a 37% decline in net profit for the fourth quarter ending March 31, 2024, as rising operational costs and margin compression weighed on the company’s bottom line. The Ahmedabad-based firm, which specializes in fermentation-based active pharmaceutical ingredients (APIs), saw its shares…